A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA - The RENEW trial

• Register: EUCTR
• Last refreshed on: 4 April 2022
• Main ID: EUCTR2008-006177-32-FR
• Date of registration: 23/10/2009
• Prospective Registration: Yes
• Primary sponsor: Celgene Corporation
• Public title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA - The RENEW trial
• Scientific title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA - The RENEW trial
• Date of first enrolment: 16/12/2009
• Target sample size: 382
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006177-32
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Czech Republic, France, Germany, Italy, Portugal, Spain, United Kingdom

Key inclusion & exclusion criteria

Inclusion criteria:
1. Must understand and voluntarily sign an informed consent form

2. Must be = 18 years of age at the time of signing the informed consent form

3. Must be able to adhere to the study visit schedule and other protocol requirements

4. Histologically-proven mantle cell non-Hodgkin’s lymphoma, including evidence of cyclin D1 overexpression by immunohistochemistry. In patients whose tumors are negative for the cyclin D1 overexpression, evidence of overexpression of cyclin D2 or D3 by immunohistochemistry will be acceptable

5. Must have received one of the following first-line induction chemotherapy regimens with rituximab:
a. A combination regimen containing all of the following components: cyclophosphamide, vincristine, adriamycin and a glucocorticoid. For example: R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP 14, R-CHOP 21; (minimum of 6 full dosed cycles up to maximum 8 cycles). Regimens containing cytarabine, or methotrexate are not allowed.
b. Fludarabine containing regimen such as FC (fludarabine, cyclophosphamide) (minimum of 6 full dosed cycles)
c. Patients who have been treated with less than 6 cycles of R-CHOP or R-FC, but received =4 cycles, can be considered eligible if dose reduction or treatment discontinuation occurred due to severe drug related toxicity, including, but not limited to: cardiac insufficiency, neurotoxicity, drug induced or worsened diabetes mellitus, repetitive febrile neutropenia and severe infections despite appropriate growth factor support, life threatening allergic reactions and the physician considers that adequate treatment has been delivered
d. Clinically appropriate dose modifications of vincristine or prednisone in the first-line induction chemotherapy regimen will be allowed if occurred in cycles =4

6. Must have completed the first-line induction chemotherapy regimen and achieved a PR or better response as assessed by 2007 Revised Response Criteria for Malignant Lymphoma (Cheson, 2007)

7. Must have completed last dose of first-line induction chemotherapy no less than 4 weeks (28 days) and no later than 12 weeks (84 days) prior to randomization

8. Patients whom the physician considers ineligible for transplant at the time of enrollment because of one of the following reasons:
a. Age = 65 years
b. Comorbidity for patients < 65 years
Comorbidity is defined as any condition including laboratory abnormalities or clinical symptoms such as e.g. cardiac insufficiency and severe pulmonary diseases that places the patient at an unacceptable risk if he/she undergoes transplant
c. Patient declines transplant

9. Eastern Cooperative Oncology Group (ECOG) performance status score of = 2 at the time of screening

10. Female of child bearing potential must:
a. Have two negative medically supervised urine pregnancy test prior to starting of study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the patient practices complete and continued sexual abstinence
b. Either commit to continued abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy

11. Male patients must:
a. Agree to use a condom during sexual con
Exclusion criteria:
1. Histology other than MCL, for example transformed lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma

2. Patients who do not have archival tumor samples and who do have no tumor accessible for biopsy are not eligible into the study

3. Patients who have received more than 1 line of induction chemotherapy

4. Patients who received 1st line induction therapy other than those specified in inclusion criteria or had treatment modification as follows:
a. Addition of new drugs to the first-line induction chemotherapy specified in inclusion criteria will not be allowed. For example, addition of cytarabine or methotrexate to R-CHOP/R-CHOP-like etc will not be allowed
b. Switching of regimens in the middle of induction treatment will not be allowed. For example, CHOP to FC or CHOP to CVP (cyclophosphamide, vincristine, and prednisone), etc will not be allowed
c. Use of any agents as "maintenance" following completion of initial combination chemotherapy are not allowed

5. Patients who have received less than 4 cycles of R-CHOP, R-CHOP-like, or R-FC are ineligible

6. Patients who achieved stable disease or progressive disease as best response with first line-induction chemotherapy

7. Any of the following laboratory abnormalities:
a. Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L)
b. Platelet count < 60,000/mm3 (60 x 109/L)
c. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT)) > 3.0 x upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma
d. Serum bilirubin > 1.5 x ULN, except in case of Gilbert's Syndrome and documented liver involvement by lymphoma

8. Calculated creatinine clearance (i.e. Cockcroft-Gault formula) of < 30 mL /min

9. Active or any history of central nervous system (CNS) lymphoma or leptomeningeal involvement by lymphoma

10. Patients should not be receiving corticosteroids except for prednisone = 10 mg/day or equivalent for purposes other than treating MCL

11. Patients at high risk for deep vein thrombosis (DVT) not willing to take DVT prophylaxis

12. Prior history of malignancies other than MCL unless the patient has been free of the disease for = 3 years. Exceptions include the following:
a. Basal cell carcinoma of the skin
b. Squamous cell carcinoma of the skin
c. Carcinoma in situ of the cervix
d. Carcinoma in situ of the breast
e. Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)

13. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form

14. Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible

15. Pregnant or lactating females

16. Uncontrolled intercurrent illness including, but not limited to:
a. Ongoing or active infection requiring parenteral antibiotics
b. Uncontrolled diabetes mellitus as defined by the investigator
c. Chronic symptomatic congestive heart failure (Class III or IV of the New York Heart Association Classification for Heart Disease)
d.Unstable angina pectoris, angioplasty, stenting, or myocardial infarctions within 6 months
e. Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia. Pat

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Mantle-Cell Lymphoma
MedDRA version: 12.0 Level: HLT Classification code 10026798 Term: Mantle cell lymphomas

Intervention(s)

Trade Name: Revlimid 5mg, hard capsules
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: LENALIDOMIDE
CAS Number: 191732-72-6
Current Sponsor code: CC-5013
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Trade Name: Revlimid 10mg, hard capsules
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: LENALIDOMIDE
CAS Number: 191732-72-6
Current Sponsor code: CC-5013
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Trade Name: Revlimid 15mg, hard capsules
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: LENALIDOMIDE
CAS Number: 191732-72-6
Current Sponsor code: CC-5013
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use

Primary Outcome(s)

Secondary Objective: To evaluate the safety of lenalidomide as maintenance therapy after completion of first-line combination chemotherapy in patients with MCL who are not candidates for transplantation and have achieved partial or complete response.

Primary end point(s): Progression Free Survival (PFS)

Main Objective: To evaluate the efficacy of lenalidomide as maintenance therapy after completion of first-line combination chemotherapy in patients with mantle cell lymphoma (MCL) who are not candidates for transplantation and have achieved partial response (PR) or complete response (CR).

Secondary ID(s)

2008-006177-32-CZ

CC-5013-MCL-003

Ethics review

Status: Approved
Approval date: 28/10/2009
Contact:

Results

• Results available: Yes
• Date Posted: 20/04/2016
• Date Completed: 02/03/2011
• URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-006177-32/results